PharmaSolv Consulting
Pharmaceutical Solutions From Discovery Through Development
Helping you improve the druggability and formulability of your drug compound
Helping you improve the druggability and formulability of your drug compound
• What salt form of the drug substance or active pharmaceutical ingredient should I choose?
• Does my salt disproportionate in the formulation (solution, suspensions, parenteral formulations, solid oral dosage forms…)?
• What polymorph?
• Should I select an amorphous phase?
• What formulation should I select to maximize exposures?
• What vehicle should be used when dosing rodents/non-rodents orally, parenterally (injectable)?
• What formulation should be used in pre-clinical tox studies?
• Can formulation solve my exposure issues?
• Can changing the form of the drug compound help?
• How can I maximize plasma exposures?
• How can I reduce variability in plasma exposures?
• What is happening to the drug substance during formulation development?
• What excipients should I avoid in my formulations?
• Why do the plasma concentrations decrease?
• Does my API crystallize from the amorphous solid dispersion formulations?
• Does it convert to a new polymorph?
• Does the salt disproportionate in the dosage form?
